/
Oncology
Glioblastoma
150
Pipeline Programs↗
241
Active Trials↗
111
Companies Involved↗
Glioblastoma is a highly competitive landscape with 150 programs across 111 companies. The most active players are Novartis, Beijing Pearl Biotechnology Limited Liability Company, Laminar Pharmaceuticals. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical22
Phase 149
Phase 266
Phase 313
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
98 of 127 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 127 classified programs, each share of the total. Modality classified for 93% of 150 pipeline programs.
Analysis
Trial Status
657
clinical trials
Completed233 · 35%
Recruiting110 · 17%
Active, not recruiting88 · 13%
Terminated81 · 12%
Unknown status57 · 9%
Not yet recruiting41 · 6%
Other47 · 7%
Clinical Trials
Trial Activity
657 trials
GlobAl Psychological and Psychiatric prOfile in Glioblastoma and Head and Neck Cancer paTients
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT06385132·207 enrolled
Page 1 of 44
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)